+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 282 Pages
  • November 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5229525
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis - Pipeline Review, H2 2020, provides an overview of the Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline landscape.

Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 8, 5, 13, 1, 19 and 8 respectively.

Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ankylosing Spondylitis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Musculoskeletal Disorders)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

Ankylosing Spondylitis - Overview

Ankylosing Spondylitis - Therapeutics Development

Ankylosing Spondylitis - Therapeutics Assessment

Ankylosing Spondylitis - Companies Involved in Therapeutics Development

Ankylosing Spondylitis - Drug Profiles

Ankylosing Spondylitis - Dormant Projects

Ankylosing Spondylitis - Discontinued Products

Ankylosing Spondylitis - Product Development Milestones

Appendix

List of Tables
  • Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by 3SBio Inc, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AbbVie Inc, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Akeso Inc, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Alvotech ehf, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Amgen Inc, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Annji Pharmaceutical Co Ltd, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Beijing Eastern Biotech Co Ltd, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Beijing Shenzhou Cell Biotechnology Group Co Ltd, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bio-Thera Solutions Ltd, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocad, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Ltd, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by BioXpress Therapeutics SA, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Clover Biopharmaceuticals, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H2 2020
  • Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 3SBio Inc
  • AbbVie Inc
  • Akeso Inc
  • Alvotech ehf
  • Amgen Inc
  • Annji Pharmaceutical Co Ltd
  • Beijing Eastern Biotech Co Ltd
  • Beijing Shenzhou Cell Biotechnology Group Co Ltd
  • Bio-Thera Solutions Ltd
  • Biocad
  • Biocon Ltd
  • BioXpress Therapeutics SA
  • Clover Biopharmaceuticals
  • DNX Biopharmaceuticals Inc
  • Eli Lilly and Co
  • Enzene Biosciences Ltd
  • FunPep Co Ltd
  • Galapagos NV
  • Hengenix Biotech Inc
  • Huabo Biopharm Co Ltd
  • Hualan Biological Engineering Inc
  • Iltoo Pharma
  • Immunwork Inc
  • InSight Biopharmaceuticals Ltd
  • Izana Bioscience Ltd
  • Jiangsu Carephar Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • JiangSu Qyuns Therapeutics Co Ltd
  • Luye Pharma Group Ltd
  • Mabpharm Ltd
  • Mycenax Biotech Inc
  • NeuClone Pty Ltd
  • Nichi-Iko Pharmaceutical Co Ltd
  • Nimbus Therapeutics LLC
  • North China Pharmaceutical Group New Drug Research and Development Co Ltd
  • Novartis AG
  • Pfizer Inc
  • Pharmapraxis
  • RNAx Ltd
  • Roivant Sciences Ltd
  • Shandong Danhong Pharmaceutical Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Siam Bioscience Co Ltd
  • Sichuan Haisco Pharmaceutical Co Ltd
  • Sino Biopharmaceutical Ltd
  • siRNAgen Therapeutics Corp
  • Sun Pharma Advanced Research Company Ltd
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • UCB SA
  • Wuhan Institute of Biological Products Co Ltd
  • Xbrane Biopharma AB